Biochem Pharmacol 80:17271735 Tan TM, Field BC, McCullough KA et al (2013) Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia
If you experience a suspected side effect from any medicine, including within a clinical trial, you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk
In cosmetics, it is used for its ability to: Neutralise free radicals: Thanks to its antioxidant action, it helps to protect skin cells from damage caused by free radicals, which can cause wrinkles and loss of firmness
The side effect is usually manageable through dietary modifications, over-the-counter remedies, and time as your body adapts
They enhance glycemic control by stimulating insulin secretion and suppressing glucagon production in response to energy intake (Neumiller, 2015)